Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fol-BRITe: B-R Followed by Zevalin in Untreated Follicular Lymphoma
NCT01234766Phase 2Completed
- Sponsor
- Dartmouth Health
- Start
- Oct 2010
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, rituximab, ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Dartmouth Health. Started Oct 2010; status: completed.
02
Drugs
bendamustinerituximabibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01234766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234766.